These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35880452)

  • 1. Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.
    Goggin C; Stansfeld A; Mahalingam P; Thway K; Smith MJ; Huang P; Jones RL; Napolitano A
    Future Oncol; 2022 Aug; 18(26):2967-2978. PubMed ID: 35880452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with
    George S; Blay JY; Chi P; Jones RL; Serrano C; Somaiah N; Gelderblom H; Zalcberg JR; Reichmann W; Sprott K; Cox P; Sherman ML; Ruiz-Soto R; Heinrich MC; Bauer S
    Future Oncol; 2024; 20(27):1973-1982. PubMed ID: 39229786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
    Heinrich MC; Jones RL; George S; Gelderblom H; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Siontis BL; Goldstein D; Boye K; Sanchez C; Steeghs N; Rutkowski P; Druta M; Serrano C; Somaiah N; Chi P; Reichmann W; Sprott K; Achour H; Sherman ML; Ruiz-Soto R; Blay JY; Bauer S
    Nat Med; 2024 Feb; 30(2):498-506. PubMed ID: 38182785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy].
    Lemaître J; Watson S
    Bull Cancer; 2022 Mar; 109(3):250-252. PubMed ID: 35094842
    [No Abstract]   [Full Text] [Related]  

  • 5. Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.
    Nemunaitis J; Bauer S; Blay JY; Choucair K; Gelderblom H; George S; Schöffski P; Mehren MV; Zalcberg J; Achour H; Ruiz-Soto R; Heinrich MC
    Future Oncol; 2020 Jan; 16(1):4251-4264. PubMed ID: 31755321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.
    Mühlenberg T; Falkenhorst J; Schulz T; Fletcher BS; Teuber A; Krzeciesa D; Klooster I; Lundberg M; Wilson L; Lategahn J; von Mehren M; Grunewald S; Tüns AI; Wardelmann E; Sicklick JK; Brahmi M; Serrano C; Schildhaus HU; Sievers S; Treckmann J; Heinrich MC; Raut CP; Ou WB; Marino-Enriquez A; George S; Rauh D; Fletcher JA; Bauer S
    J Clin Oncol; 2024 Apr; 42(12):1439-1449. PubMed ID: 38408285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.
    Di Vito A; Ravegnini G; Gorini F; Aasen T; Serrano C; Benuzzi E; Coschina E; Monesmith S; Morroni F; Angelini S; Hrelia P
    Pharmacol Ther; 2023 Aug; 248():108475. PubMed ID: 37302758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
    Sargsyan A; Kucharczyk MA; Jones RL; Constantinidou A
    Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):119-127. PubMed ID: 36644853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
    Lee DM; Sun A; Patil SS; Liu L; Rao AV; Trent PT; Ali AA; Liu C; Rausch JL; Presutti LD; Kaczorowski A; Schneider F; Amankulor NM; Shuda M; Duensing A
    Sci Rep; 2022 May; 12(1):8275. PubMed ID: 35585158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
    Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
    Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
    Serrano C; Bauer S
    Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
    Banks E; Grondine M; Bhavsar D; Barry E; Kettle JG; Reddy VP; Brown C; Wang H; Mettetal JT; Collins T; Adeyemi O; Overman R; Lawson D; Harmer AR; Reimer C; Drew L; Packer MJ; Cosulich S; Jones RD; Shao W; Wilson D; Guichard S; Fawell S; Anjum R
    Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32350132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gastrointestinal stromal tumors (GIST)].
    Jaros D; Bozic B; Sebesta C
    Wien Med Wochenschr; 2023 Jun; 173(9-10):201-205. PubMed ID: 36155864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
    Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
    Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next questions for the medical treatment of gastrointestinal stromal tumor.
    Italiano A
    Curr Opin Oncol; 2022 Jul; 34(4):348-353. PubMed ID: 35730519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.
    Huang WK; Wu CE; Wang SY; Chang CF; Chou WC; Chen JS; Yeh CN
    Curr Treat Options Oncol; 2022 Sep; 23(9):1303-1319. PubMed ID: 35976553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
    Bauer S; Jones RL; Blay JY; Gelderblom H; George S; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Su Y; Meade J; Wang T; Sherman ML; Ruiz-Soto R; Heinrich MC
    J Clin Oncol; 2022 Dec; 40(34):3918-3928. PubMed ID: 35947817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors.
    Khosroyani HM; Klug LR; Heinrich MC
    Drugs; 2023 Jan; 83(1):55-73. PubMed ID: 36607590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.
    Cicala CM; Olivares-Rivas I; Aguirre-Carrillo JA; Serrano C
    Expert Opin Investig Drugs; 2024 Mar; 33(3):159-170. PubMed ID: 38344849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ripretinib: First Approval.
    Dhillon S
    Drugs; 2020 Jul; 80(11):1133-1138. PubMed ID: 32578014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.